Turn Therapeutics Q2 net loss $5.85M; GX-03 Phase 2 interim data positive, expands study

Turn Therapeutics Inc.

Net loss $5.85M (-$0.20/share) vs $1.24M (-$0.05) in Q2 2025; cash $10.3M, runway into Q3 2027.
GX-03 Phase 2 interim: 61.5% vs 8.3% clear/almost clear at Week 4; EASI-75 69.2% vs 25.0% at Week 4.
Expanded Stage 2 to 120-135 patients including lower EASI; no serious adverse events; enrollment on track for Q4 2026.
Appointed former FDA Commissioner Stephen Hahn as Executive Clinical and Regulatory Lead on May 18, 2026.
Plans Phase 2a in hidradenitis suppurativa (~60 patients) targeting first dosing Q2 2027; first peer-reviewed publication May 27, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.